NEW YORK (GenomeWeb News) – Traversa Therapeutics, a La Jolla, Calif.-based developer of RNAi delivery technologies, today announced that it has raised $2 million in a Series A financing round.
Traversa’s technology was developed by Steven Dowdy, a Howard Hughes Medical Institute investigator at the University of California, San Diego.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Technology Review reports that researchers in the US have used CRISPR to modify a number of human embryos.

Plant researchers plan to sequence some 10,000 samples that represent the major plant clades, ScienceInsider reports.

By introducing genes from butterfly peas and Canterbury bells, researchers in Japan have developed a blue chrysanthemum, according to NPR.

In Nature this week: a Danish reference genome, and more.